Haploidentical Transplantation With Early Adoptive Transfer of CD56+CD3- NK Cells

Launched by CHARITE UNIVERSITY, BERLIN, GERMANY · Oct 13, 2010

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Patients with AML or ALL in first CR with the following high risk features:
• • 1. AML with aberration Del (5q) -5, del (7q) -7, t(9;22) or t(6;9), abn 3q, 9q, 11q, 20q, 21q, 17p;
• • 2. AML with a complex caryotype;
• • 3. secondary AML after previous chemo- or radiotherapy or MDS;
• • 4. Ph-positive ALL
• • Patients with AML or ALL after induction failure or in second CR
• • Patients with CML in second chronic or accelerated phase
• * Patients with malignant Lymphoma and the following high risk features:
• • 1. relapse after autologous transplantation
• • 2. primary chemotherapy refractory disease
• * All patients must fulfill the following criteria:
• • 1. lack of a suitable HLA-identical family, unrelated or cord blood donor
• • 2. no active infection, no severe impairment of cardial, pulmonary, renal and hepatic function
• • 3. blast count in the marrow \< 30%
• • 4. informed consent
• Exclusion Criteria:
• • active infection, no severe impairment of cardial, pulmonary, renal and hepatic function
• • blast count in the marrow \> 30%
• • unable or unwilling to sign and/or understand informed consent